ID   SK-N-BE(2)
AC   CVCL_0528
SY   SK-N-BE2; SK-N-BE-2; SKNBE(2); SKNBE-2; SKNBE2; SK-N-BE; SKNBE
DR   BTO; BTO:0002696
DR   CLO; CLO_0009052
DR   MCCL; MCC:0000505
DR   CLDB; cl4332
DR   CLDB; cl4333
DR   Abcam; ab275476
DR   ArrayExpress; E-MTAB-2770
DR   ATCC; CRL-2271
DR   BCRJ; 0381
DR   BioGRID_ORCS_Cell_line; 375
DR   BioSample; SAMN03472880
DR   BioSample; SAMN03473451
DR   BioSample; SAMN10988136
DR   cancercelllines; CVCL_0528
DR   CCRID; 3101HUMTCHu200
DR   Cell_Model_Passport; SIDM00894
DR   CLS; 305058
DR   Cosmic; 1019928
DR   Cosmic; 2485941
DR   DepMap; ACH-000312
DR   DSMZ; ACC-632
DR   DSMZCellDive; ACC-632
DR   ECACC; 95011815
DR   GEO; GSM554389
DR   GEO; GSM563358
DR   GEO; GSM692869
DR   GEO; GSM827352
DR   GEO; GSM887593
DR   GEO; GSM888676
DR   GEO; GSM1366411
DR   GEO; GSM1670450
DR   GEO; GSM2371255
DR   GEO; GSM2394375
DR   IARC_TP53; 30154
DR   ICLC; HTL96015
DR   KCB; KCB 2011099YJ
DR   LiGeA; CCLE_929
DR   LINCS_LDP; LCL-1980
DR   MetaboLights; MTBLS104
DR   PharmacoDB; SKNBE_2_1405_2019
DR   PRIDE; PXD002635
DR   Progenetix; CVCL_0528
DR   Wikidata; Q54954442
RX   DOI=10.1007/0-306-46872-7_2;
RX   DOI=10.1007/978-1-4757-1647-4_13;
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RX   PubMed=29704;
RX   PubMed=62055;
RX   PubMed=2535691;
RX   PubMed=6582512;
RX   PubMed=7838528;
RX   PubMed=11507071;
RX   PubMed=11550280;
RX   PubMed=15720811;
RX   PubMed=15892104;
RX   PubMed=16822308;
RX   PubMed=20215515;
RX   PubMed=20631050;
RX   PubMed=20655465;
RX   PubMed=22213050;
RX   PubMed=22460905;
RX   PubMed=24792489;
RX   PubMed=25877200;
RX   PubMed=25884760;
RX   PubMed=28350380;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   http://www.cccells.org/dl/NB_Data_Sheets/SK-N-BE2_Cell_Line_Data_Sheet_COGcell_org.pdf
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/s/cell-lines-detail-565.html
WW   https://www.mskcc.org/research-advantage/support/technology/tangible-material/sk-n-be-2-human-neuroblastoma-cell-line
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-530.
CC   Population: Caucasian.
CC   Characteristics: Substrate-adherent type (S-type) (PubMed=15720811).
CC   Doubling time: 27 hours (PubMed=29704); ~36 hours (DSMZ=ACC-632).
CC   Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (from child cell line SK-N-BE(2)-C).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Homozygous (PubMed=11507071; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative phosphoproteome analysis.
CC   Omics: Deep tyrosine phosphoproteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Metabolome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.71%; Native American=0.88%; East Asian, North=1.41%; East Asian, South=0%; South Asian=7.87%; European, North=24.66%; European, South=63.46% (PubMed=30894373).
CC   Discontinued: Abcam; ab275476; true.
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): ATCC; CCRID; COG; DSMZ; PubMed=25877200
ST   Amelogenin: X (DSMZ)
ST   Amelogenin: X,Y (ATCC; CCRID; COG; PubMed=25877200)
ST   CSF1PO: 10
ST   D13S317: 11
ST   D16S539: 9,11
ST   D18S51: 14 (DSMZ)
ST   D18S51: 14,16 (CCRID; PubMed=25877200)
ST   D18S51: 16 (COG)
ST   D19S433: 12,13
ST   D21S11: 30,31,32.2 (CCRID; PubMed=25877200)
ST   D21S11: 30,32.2 (COG; DSMZ)
ST   D2S1338: 17,23
ST   D3S1358: 19
ST   D5S818: 12
ST   D7S820: 9,10
ST   D8S1179: 13,14
ST   FGA: 22,25
ST   Penta D: 13,14
ST   Penta E: 14,18
ST   TH01: 6 (DSMZ)
ST   TH01: 6,7 (ATCC; CCRID; COG; PubMed=25877200)
ST   TPOX: 8,11
ST   vWA: 18
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_9898 ! SK-N-BE(1)
SX   Male
AG   2Y2M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 41
//
RX   DOI=10.1007/0-306-46872-7_2;
RA   Thiele C.J.;
RT   "Neuroblastoma.";
RL   (In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999).
//
RX   DOI=10.1007/978-1-4757-1647-4_13;
RA   Biedler J.L.;
RT   "Chromosome abnormalities in human tumor cells in culture.";
RL   (In) Human tumor cells in vitro; Fogh J. (eds.); pp.359-394; Springer; New York (1975).
//
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RA   Israel M.A., Thiele C.J.;
RT   "Tumor cell lines of the peripheral nervous system.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York (1994).
//
RX   PubMed=29704;
RA   Biedler J.L., Roffler-Tarlov S., Schachner M., Freedman L.S.;
RT   "Multiple neurotransmitter synthesis by human neuroblastoma cell lines
RT   and clones.";
RL   Cancer Res. 38:3751-3757(1978).
//
RX   PubMed=62055; DOI=10.1093/jnci/57.3.683;
RA   Biedler J.L., Spengler B.A.;
RT   "A novel chromosome abnormality in human neuroblastoma and
RT   antifolate-resistant Chinese hamster cell lives in culture.";
RL   J. Natl. Cancer Inst. 57:683-695(1976).
//
RX   PubMed=2535691;
RA   Ciccarone V., Spengler B.A., Meyers M.B., Biedler J.L., Ross R.A.;
RT   "Phenotypic diversification in human neuroblastoma cells: expression
RT   of distinct neural crest lineages.";
RL   Cancer Res. 49:219-225(1989).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=7838528;
RA   Cheng N.C., Van Roy N., Chan A., Beitsma M., Westerveld A.,
RA   Speleman F., Versteeg R.;
RT   "Deletion mapping in neuroblastoma cell lines suggests two distinct
RT   tumor suppressor genes in the 1p35-36 region, only one of which is
RT   associated with N-myc amplification.";
RL   Oncogene 10:291-297(1995).
//
RX   PubMed=11507071;
RA   Keshelava N., Zuo J.J., Chen P., Waidyaratne S.N., Luna M.C.,
RA   Gomer C.J., Triche T.J., Reynolds C.P.;
RT   "Loss of p53 function confers high-level multidrug resistance in
RT   neuroblastoma cell lines.";
RL   Cancer Res. 61:6185-6193(2001).
//
RX   PubMed=11550280; DOI=10.1002/gcc.1174;
RA   Van Roy N., Van Limbergen H., Vandesompele J., Van Gele M., Poppe B.,
RA   Salwen H.R., Laureys G., Manoel N., De Paepe A., Speleman F.;
RT   "Combined M-FISH and CGH analysis allows comprehensive description of
RT   genetic alterations in neuroblastoma cell lines.";
RL   Genes Chromosomes Cancer 32:126-135(2001).
//
RX   PubMed=15720811; DOI=10.1593/neo.04310;
RA   Walton J.D., Kattan D.R., Thomas S.K., Spengler B.A., Guo H.-F.,
RA   Biedler J.L., Cheung N.-K.V., Ross R.A.;
RT   "Characteristics of stem cells from human neuroblastoma cell lines and
RT   in tumors.";
RL   Neoplasia 6:838-845(2004).
//
RX   PubMed=15892104; DOI=10.1002/gcc.20198;
RA   Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K., Khazi D.,
RA   Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L.,
RA   Maris J.M.;
RT   "High-resolution detection and mapping of genomic DNA alterations in
RT   neuroblastoma.";
RL   Genes Chromosomes Cancer 43:390-403(2005).
//
RX   PubMed=16822308; DOI=10.1186/1471-2407-6-177;
RA   Dam V., Morgan B.T., Mazanek P., Hogarty M.D.;
RT   "Mutations in PIK3CA are infrequent in neuroblastoma.";
RL   BMC Cancer 6:177.1-177.10(2006).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20631050; DOI=10.1101/gr.106252.110;
RA   Storlazzi C.T., Lonoce A., Guastadisegni M.C., Trombetta D.,
RA   D'Addabbo P., Daniele G., L'Abbate A., Macchia G., Surace C., Kok K.,
RA   Ullmann R., Purgato S., Palumbo O., Carella M., Ambros P.F.,
RA   Rocchi M.;
RT   "Gene amplification as double minutes or homogeneously staining
RT   regions in solid tumors: origin and structure.";
RL   Genome Res. 20:1198-1206(2010).
//
RX   PubMed=20655465; DOI=10.1016/j.cell.2010.06.004;
RA   Holzel M., Huang S.-D., Koster J., Ora I., Lakeman A., Caron H.N.,
RA   Nijkamp W., Xie J., Callens T., Asgharzadeh S., Seeger R.C.,
RA   Messiaen L.M., Versteeg R., Bernards R.;
RT   "NF1 is a tumor suppressor in neuroblastoma that determines retinoic
RT   acid response and disease outcome.";
RL   Cell 142:218-229(2010).
//
RX   PubMed=22213050; DOI=10.1002/ijc.27415;
RA   Gawecka J.E., Geerts D., Koster J., Caliva M.J., Sulzmaier F.J.,
RA   Opoku-Ansah J., Wada R.K., Bachmann A.S., Ramos J.W.;
RT   "PEA15 impairs cell migration and correlates with clinical features
RT   predicting good prognosis in neuroblastoma.";
RL   Int. J. Cancer 131:1556-1568(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=24792489; DOI=10.1007/s11060-014-1456-8;
RA   Farooqi A.S., Dagg R.A., Choi L.M.R., Shay J.W., Reynolds C.P.,
RA   Lau L.M.S.;
RT   "Alternative lengthening of telomeres in neuroblastoma cell lines is
RT   associated with a lack of MYCN genomic amplification and with p53
RT   pathway aberrations.";
RL   J. Neurooncol. 119:17-26(2014).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25884760; DOI=10.1371/journal.pcbi.1004130;
RA   Palacios-Moreno J., Foltz L., Guo A.-L., Stokes M.P., Kuehn E.D.,
RA   George L., Comb M.J., Grimes M.L.;
RT   "Neuroblastoma tyrosine kinase signaling networks involve FYN and LYN
RT   in endosomes and lipid rafts.";
RL   PLoS Comput. Biol. 11:e1004130.1-e1004130.33(2015).
//
RX   PubMed=28350380; DOI=10.1038/sdata.2017.33;
RA   Harenza J.L., Diamond M.A., Adams R.N., Song M.M., Davidson H.L.,
RA   Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.;
RT   "Transcriptomic profiling of 39 commonly-used neuroblastoma cell
RT   lines.";
RL   Sci. Data 4:170033-170033(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//